[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
In case study, we presented patient with glioblastoma multiforme-brain tumor-grade IV-WHO. Patient after surgery, followed by radiotherapy and chemotherapy, after cycles of chemotherapy with temozolomid. During therapy with temozolomid, it is recommended to check morphology on the 22nd day of cycle. Patient did not come for follow-up appointment, also she did not do any of follow-up tests. She came to the hospital 2 weeks later, in poor general condition with peripheral pancytopenia, neurological disorders and shortness of breath.
Łata
Stanisław
S
Szpital Wojewódzki im. Sw. Łukasza Tarnów Oddział Wewnetrzny II i Ostrych Zatruć.
Molczyk
Anna
A
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced*; D010198:Pancytopenia / Q000139:chemically induced*; D018714:Radiotherapy, Adjuvant; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide